IL21 and central nervous system cancer: With this combined generality and accuracy, the model can potentially accommodate other clinical settings and solid cancers where similar immune processes apply and where IL-21 has been useful (i.e. adenocarcinoma, glioma, neuroblastoma) [7],[8].